3 November 2026
Latham & Watkins Advises on Bambusa Therapeutics’ Upsized US$168.9 Million IPO
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Alison Haggerty Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Rachel Moore | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Sam Berry | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 169m (US$168.9 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Bambusa Therapeutics, Inc. (Issuer)